Levodropropizine is the levorotatory of the racemic antitussive agent dropropizine. It is indicated for the symptomatic treatment of nonproductive coughs. Structurally, levodropropizine is the levorotatory isomer of the racemic antitussive agent dropropizine. Compared with the racemate, levodropropizine shows reduced sedative effects and an improved tolerability profile. Levodropropizine does not bind to beta-adrenergic, muscarinic, and opiate receptors, but it shows some affinity for histamine (H1) and alpha-adrenergic receptors. Levodropropizine also shows some local anesthetic activity in animal models.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Levodropropizine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.